APA (7th ed.) Citation

F, M., AM, T., ML, M., L, P., L, L., M, M., & A, D. R. (2022). Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL). Leukemia & lymphoma, 63(2), 483. https://doi.org/10.1080/10428194.2021.1978091

Chicago Style (17th ed.) Citation

F, Malfona, Testi AM, Moleti ML, Petrucci L, Leccisotti L, Martelli M, and Di Rocco A. "Efficacy of Ibrutinib as Salvage Treatment in a Secondary Central Nervous System Lymphoma (SCNSL) Progressed After Chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL)." Leukemia & Lymphoma 63, no. 2 (2022): 483. https://doi.org/10.1080/10428194.2021.1978091.

MLA (9th ed.) Citation

F, Malfona, et al. "Efficacy of Ibrutinib as Salvage Treatment in a Secondary Central Nervous System Lymphoma (SCNSL) Progressed After Chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL)." Leukemia & Lymphoma, vol. 63, no. 2, 2022, p. 483, https://doi.org/10.1080/10428194.2021.1978091.